Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 132

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 132
---
 public shares subject to possible redemption outstanding at , 2025, are redeemed for an aggregate redemption payment of approximately $9.1 million. This maximum redemption scenario reflects the maximum number of public shares that can be redeemed without violating the conditions of the Merger Agreement.

| Sources of Funds(1)                                     |     |   |         |     | Uses of Funds(1)                                    |     |   |             |   |
|:--------------------------------------------------------|:----|:--|--------:|:----|:----------------------------------------------------|:----|:--|------------:|:--|
| Cash balance of Semnur prior to Business Combination(2) |     | $ |   7,379 |     | Denali Class A Ordinary Shares public redemption(4) |     | $ |     535,667 |   |
| Cash balance of Denali prior to Business Combination(2) |     |   |   2,736 |     | Transaction Fees and                                
 Expenses(5)                                         |     |   |  20,169,958 |   |
| Existing Cash held in Trust                             
 Account(3)                                              |     |   | 535,667 |     | Payment of Denali Promissory                        
 Notes(6)                                            |     |   |   2,986,380 |   |
|                                                         |     |   |         |     | Remaining Cash on Balance Sheet(7)                  |     |   | (23,146,223 | ) |
| Total Sources                                           |     | $ | 545,782 |     | Total Uses                                          |     | $ |     545,782 |   |

| (1) | Totals may be affected by rounding. |

| (2) | As of March 31, 2025. |

| (3) | Reflects cash plus accrued interest as of April 15, 2025. |

| (4) | Reflects the redemption of Denali Class A Ordinary Shares by public stockholders. |

| (5) | Reflects the repayment of an estimated legal, audit, consulting and other transaction-related expenses. |

| (6) | Reflects the estimated repayment amount of the Denali Promissory Notes due to the Sponsor, FutureTech and Scilex of $2,986,380 in aggregate principal and interest as of June 30, 2025, assuming each monthly extension fee payment is made through June 2025. |

| (7) | Reflects the cash